About

This information supports the use of the Argatroban Dose Calculator. Argatroban is a direct thrombin inhibitor used as an anticoagulant in patients with, or at risk for, heparin-induced thrombocytopenia (HIT), including during percutaneous coronary intervention (PCI). This guide outlines the key inputs, outputs, and clinical considerations for its administration and monitoring.

Outputs

The calculator provides tailored dosing recommendations based on the selected clinical scenario. Key outputs are displayed clearly for quick interpretation.

How to Use

To use the calculator effectively, follow these steps:

• Patient Weight: Enter the patient's weight and select the correct unit (kg or lbs). The tool converts lbs to kg for calculations.
• Hepatic Impairment: Specify if the patient has moderate hepatic impairment (Child-Pugh B), as this requires a lower initial dose for HIT.
• Calculation Mode: Select the appropriate clinical scenario:
  • Initial Dosing for HIT: For patients starting Argatroban for HIT.
  • Dose Adjustment for HIT: For titrating the dose based on a current aPTT value and infusion rate.
  • Dosing for PCI: To calculate the initial bolus and maintenance infusion for patients undergoing PCI.
  • Transition to Warfarin: To guide the discontinuation of Argatroban based on a measured INR while on concurrent therapy.

Dosing Overview

The calculator uses standard, evidence-based dosing protocols:

• HIT (Initial Dose): The standard starting dose is 2 mcg/kg/min. For patients with moderate hepatic impairment, this is reduced to 0.5 mcg/kg/min.
• HIT (Dose Adjustment): The goal is to maintain the activated partial thromboplastin time (aPTT) at 1.5 to 3 times the initial baseline value, not to exceed 100 seconds. The calculator adjusts the dose based on aPTT results to achieve a target of approximately 50-70 seconds.
• PCI: Dosing consists of an initial bolus of 350 mcg/kg administered over 3-5 minutes, followed by a maintenance infusion of 25 mcg/kg/min. The target activated clotting time (ACT) is 300-450 seconds.

Switching

When transitioning from Argatroban to an oral anticoagulant like warfarin, careful monitoring is required because Argatroban can independently increase the International Normalized Ratio (INR).

• Co-administration of Argatroban (at doses up to 2 mcg/kg/min) and warfarin is recommended.
• The Argatroban infusion should continue until the INR is in the therapeutic range on warfarin alone.
• The calculator recommends stopping Argatroban when the INR is >4 on concurrent therapy.
• After stopping Argatroban, the INR should be rechecked in 4-6 hours to ensure it remains in the desired therapeutic range (typically 2-3).

Missed Dose

Argatroban is administered as a continuous intravenous infusion and has a short half-life (approximately 45 minutes). An interruption in the infusion will lead to a rapid loss of anticoagulant effect. If the infusion is stopped or interrupted, it should be restarted as soon as possible according to institutional protocol. The calculator can be used to re-verify the correct infusion rate upon resumption of therapy.

Safety Alerts

• Bleeding Risk: The most common complication is bleeding. Use with caution in patients with bleeding disorders or those at high risk of hemorrhage.
• Hepatic Impairment: Argatroban is metabolized by the liver. Patients with hepatic impairment have decreased clearance, requiring significant dose reductions.
• Effect on INR: Argatroban increases the prothrombin time (PT) and INR. This must be considered when transitioning to warfarin.
• Monitoring: Regular monitoring of aPTT (for HIT) or ACT (for PCI) is essential to ensure therapeutic anticoagulation and minimize bleeding risk.

FAQ

• What concentration of Argatroban does the calculator assume?

  All calculations are based on a standard concentration of 1 mg/mL (e.g., 250 mg of Argatroban in 250 mL of diluent).

• Why is the initial dose for HIT lower with hepatic impairment?

  Argatroban is cleared by the liver. Patients with moderate hepatic impairment process the drug more slowly, so a lower starting dose (0.5 mcg/kg/min) is needed to avoid excessive anticoagulation.

• What is the target aPTT for HIT therapy?

  The target aPTT is typically 1.5 to 3 times the patient's baseline value, usually corresponding to a range of 50-70 seconds. The calculator uses this range to recommend dose adjustments.

• Can this calculator be used for patients with renal impairment?

  Yes. Argatroban clearance is not significantly affected by renal function, so no dose adjustment is typically required for renal impairment.

• How does the dose adjustment mode work?

  You input the current aPTT and infusion rate. Based on whether the aPTT is below, within, or above the target range, the calculator recommends increasing, maintaining, or decreasing the dose, or holding the infusion.

• Why does the calculator recommend stopping Argatroban only when the INR is >4 during warfarin transition?

  Because Argatroban itself elevates the INR, a higher target is needed to ensure that warfarin has reached a therapeutic level. Once Argatroban is stopped, the INR will fall to a level reflecting only the effect of warfarin.

• Does the calculator account for critically ill patients?

  The calculator provides standard dosing, but critically ill patients may require more frequent monitoring and adjustments. The starting dose for HIT in critically ill patients may also be lower (e.g., 0.5-1 mcg/kg/min) based on clinical judgment.

• Is the PCI bolus included in the infusion bag?

  The bolus is typically drawn from the prepared infusion solution and administered as a separate, rapid injection over 3-5 minutes before starting the continuous maintenance infusion.

References

• ARGATROBAN Injection - Official FDA Prescribing Information. U.S. Food and Drug Administration.
• American Society of Hematology (ASH) 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Advances.
• Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation. 2001;103(14):1838-1843.
• Jang IK, Hursting MJ. When heparin is not the right choice: the use of argatroban in patients with heparin-induced thrombocytopenia. Rev Cardiovasc Med. 2005;6 Suppl 3:S26-34.